Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children
Anna Turkova, Genevieve H Wills, Eric Wobudeya, Chishala Chabala, Megan Palmer, Aarti Kinikar, Syed Hissar, Louise Choo, Philippa Musoke, Veronica Mulenga, Vidya Mave, Bency Joseph, Kristen LeBeau, Margaret J Thomason, Robert B Mboizi, Monica Kapasa, Marieke M van der Zalm, Priyanka Raichur, Perumal K Bhavani, Helen McIlleron, Anne-Marie Demers, Rob Aarnoutse, James Love-Koh, James A Seddon, Steven B Welch, Stephen M Graham, Anneke C Hesseling, Diana M Gibb, Angela M Crook, SHINE Trial Team, Anna Turkova, Genevieve H Wills, Eric Wobudeya, Chishala Chabala, Megan Palmer, Aarti Kinikar, Syed Hissar, Louise Choo, Philippa Musoke, Veronica Mulenga, Vidya Mave, Bency Joseph, Kristen LeBeau, Margaret J Thomason, Robert B Mboizi, Monica Kapasa, Marieke M van der Zalm, Priyanka Raichur, Perumal Kannabiran Bhavani, Helen McIlleron, Anne-Marie Demers, Rob Aarnoutse, James Love-Koh, James A Seddon, Steven B Welch, Stephen M Graham, Anneke C Hesseling, Diana M Gibb, Angela M Crook, Diana M Gibb, Angela M Crook, Genevieve Wills, Margaret J Thomason, Jaqueline Teera, Ellen Owen-Powell, David Baptiste, Charlotte McGowan, Moira Spyer, Joyce Lungu, Kevin Zimba, Khozya Zyambo, Chalilwe Chungu, Chimuka Tembo, Sharon Kunda, Ellen Shingalili, Semy Zulu, Terence Chipoya, Habulembe Mwanakalanga, Elias Chambela, Jessy M Hankombo, Mox Malama Kalumbi, Daniel Chola, Stephen Malama, Mboizi Robert Baldwin, Winnie Nansamba, Mark Ssenyonga, Willy Ssengooba, Gerald Businge, Anneke C Hesseling, Jessica Workman, Simon Schaaf, Robert Gie, Elisabetta Walters, Warren Zimri, Graeme Hoddinott, Anneen van Deventer, Pierre Goussard, Julie Morrison, Aarti Avinash Kinikar, Aparna Nijampurkar, Sameer Khan, G Prathiksha, Dhanaraj Baskaran, N S Gomathi, V Mythily, Hemanth Kumar, Silambu Chelvi, L Sekar, Luke Hanna, K Ramesh, Hema Latha, S Bharathi, Parveen Banu, Dino Xavier, Manjith Kumar, K Guru, Sasi Kumar, A Kesavan, A Gunasundari, G Mangalambal, Valarmathi Nagarajan, Shakeela Shankar, R Selvi, S Vaishnavi, Krishna Yadav, R Supriya, Hema Giranab, A Seetha, Stella Mary, S Gopika, S Rohini, M Revathy, Sarath Balaji, S Elilarasi, J Ganesh, M A Aravind, Sylvia Mulambo, Hope Mwanyungwi, Dharati Tapse, Manasi Sane, Amina Abdullah, Sarah Nakalanzi, Cynthia Mukisa Williams, Paul Revill, Simon Walker, Peter Mugyenyi, Janet Darbyshire, Polly Clayden, Peter Donald, Varinder Singh, Malgosia Grzemska, Soumya Swaminathan, Tim Peto, Alwyn Mwinga, Katherine Fielding, Stephen M Graham, Steven B Welch, James A Seddon, Elizabeth Whittaker, Suzanne Anderson, Louis Grandjean, Anna Turkova, Genevieve H Wills, Eric Wobudeya, Chishala Chabala, Megan Palmer, Aarti Kinikar, Syed Hissar, Louise Choo, Philippa Musoke, Veronica Mulenga, Vidya Mave, Bency Joseph, Kristen LeBeau, Margaret J Thomason, Robert B Mboizi, Monica Kapasa, Marieke M van der Zalm, Priyanka Raichur, Perumal K Bhavani, Helen McIlleron, Anne-Marie Demers, Rob Aarnoutse, James Love-Koh, James A Seddon, Steven B Welch, Stephen M Graham, Anneke C Hesseling, Diana M Gibb, Angela M Crook, SHINE Trial Team, Anna Turkova, Genevieve H Wills, Eric Wobudeya, Chishala Chabala, Megan Palmer, Aarti Kinikar, Syed Hissar, Louise Choo, Philippa Musoke, Veronica Mulenga, Vidya Mave, Bency Joseph, Kristen LeBeau, Margaret J Thomason, Robert B Mboizi, Monica Kapasa, Marieke M van der Zalm, Priyanka Raichur, Perumal Kannabiran Bhavani, Helen McIlleron, Anne-Marie Demers, Rob Aarnoutse, James Love-Koh, James A Seddon, Steven B Welch, Stephen M Graham, Anneke C Hesseling, Diana M Gibb, Angela M Crook, Diana M Gibb, Angela M Crook, Genevieve Wills, Margaret J Thomason, Jaqueline Teera, Ellen Owen-Powell, David Baptiste, Charlotte McGowan, Moira Spyer, Joyce Lungu, Kevin Zimba, Khozya Zyambo, Chalilwe Chungu, Chimuka Tembo, Sharon Kunda, Ellen Shingalili, Semy Zulu, Terence Chipoya, Habulembe Mwanakalanga, Elias Chambela, Jessy M Hankombo, Mox Malama Kalumbi, Daniel Chola, Stephen Malama, Mboizi Robert Baldwin, Winnie Nansamba, Mark Ssenyonga, Willy Ssengooba, Gerald Businge, Anneke C Hesseling, Jessica Workman, Simon Schaaf, Robert Gie, Elisabetta Walters, Warren Zimri, Graeme Hoddinott, Anneen van Deventer, Pierre Goussard, Julie Morrison, Aarti Avinash Kinikar, Aparna Nijampurkar, Sameer Khan, G Prathiksha, Dhanaraj Baskaran, N S Gomathi, V Mythily, Hemanth Kumar, Silambu Chelvi, L Sekar, Luke Hanna, K Ramesh, Hema Latha, S Bharathi, Parveen Banu, Dino Xavier, Manjith Kumar, K Guru, Sasi Kumar, A Kesavan, A Gunasundari, G Mangalambal, Valarmathi Nagarajan, Shakeela Shankar, R Selvi, S Vaishnavi, Krishna Yadav, R Supriya, Hema Giranab, A Seetha, Stella Mary, S Gopika, S Rohini, M Revathy, Sarath Balaji, S Elilarasi, J Ganesh, M A Aravind, Sylvia Mulambo, Hope Mwanyungwi, Dharati Tapse, Manasi Sane, Amina Abdullah, Sarah Nakalanzi, Cynthia Mukisa Williams, Paul Revill, Simon Walker, Peter Mugyenyi, Janet Darbyshire, Polly Clayden, Peter Donald, Varinder Singh, Malgosia Grzemska, Soumya Swaminathan, Tim Peto, Alwyn Mwinga, Katherine Fielding, Stephen M Graham, Steven B Welch, James A Seddon, Elizabeth Whittaker, Suzanne Anderson, Louis Grandjean
Abstract
Background: Two thirds of children with tuberculosis have nonsevere disease, which may be treatable with a shorter regimen than the current 6-month regimen.
Methods: We conducted an open-label, treatment-shortening, noninferiority trial involving children with nonsevere, symptomatic, presumably drug-susceptible, smear-negative tuberculosis in Uganda, Zambia, South Africa, and India. Children younger than 16 years of age were randomly assigned to 4 months (16 weeks) or 6 months (24 weeks) of standard first-line antituberculosis treatment with pediatric fixed-dose combinations as recommended by the World Health Organization. The primary efficacy outcome was unfavorable status (composite of treatment failure [extension, change, or restart of treatment or tuberculosis recurrence], loss to follow-up during treatment, or death) by 72 weeks, with the exclusion of participants who did not complete 4 months of treatment (modified intention-to-treat population). A noninferiority margin of 6 percentage points was used. The primary safety outcome was an adverse event of grade 3 or higher during treatment and up to 30 days after treatment.
Results: From July 2016 through July 2018, a total of 1204 children underwent randomization (602 in each group). The median age of the participants was 3.5 years (range, 2 months to 15 years), 52% were male, 11% had human immunodeficiency virus infection, and 14% had bacteriologically confirmed tuberculosis. Retention by 72 weeks was 95%, and adherence to the assigned treatment was 94%. A total of 16 participants (3%) in the 4-month group had a primary-outcome event, as compared with 18 (3%) in the 6-month group (adjusted difference, -0.4 percentage points; 95% confidence interval, -2.2 to 1.5). The noninferiority of 4 months of treatment was consistent across the intention-to-treat, per-protocol, and key secondary analyses, including when the analysis was restricted to the 958 participants (80%) independently adjudicated to have tuberculosis at baseline. A total of 95 participants (8%) had an adverse event of grade 3 or higher, including 15 adverse drug reactions (11 hepatic events, all but 2 of which occurred within the first 8 weeks, when the treatments were the same in the two groups).
Conclusions: Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere, smear-negative tuberculosis. (Funded by the U.K. Medical Research Council and others; SHINE ISRCTN number, ISRCTN63579542.).
Copyright © 2022 Massachusetts Medical Society.
Figures
References
- WHO. Global Tuberculosis Report 2020. World Health Organization; Geneva: 2020. Licence: CC BY-NC-SA 3.0 IGO 2020.
- Dodd PJ, Yuen CM, Sismanidis C, Seddon JA, Jenkins HE. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health. 2017;5(9):e898–e906.
- Wiseman CA, Gie RP, Starke JR, Schaaf HS, Donald PR, Cotton MF, et al. A proposed comprehensive classification of tuberculosis disease severity in children. The Pediatric infectious disease journal. 2012;31(4):347–52.
- Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Enarson DA, Beyers N. The spectrum of disease in children treated for tuberculosis in a highly endemic area. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2006;10(7):732–8.
- Loveday M, Sunkari B, Marais BJ, Master I, Brust JC. Dilemma of managing asymptomatic children referred with ‘culture-confirmed’ drug-resistant tuberculosis. Archives of disease in childhood. 2016;101(7):608–13.
- Jaganath D, Mupere E. Childhood tuberculosis and malnutrition. The Journal of infectious diseases. 2012;206(12):1809–15.
- Martinez L, Cords O, Horsburgh CR, Andrews JR, Pediatric TBCSC. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395(10228):973–84.
- Graham SM, Grzemska M, Gie RP. The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2015;19(Suppl 1):3–8.
- WHO. Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2014.
- Chabala C, Turkova A, Thomason MJ, Wobudeya E, Hissar S, Mave V, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials. 2018;19(1):237.
- Wademan DT, Busakwe L, Nicholson TJ, van der Zalm M, Palmer M, Workman J, et al. Acceptability of a first-line anti-tuberculosis formulation for children: qualitative data from the SHINE trial. Int J Tuberc Lung Dis. 2019;23(12):1263–8.
- Graham SM, Cuevas LE, Jean-Philippe P, Browning R, Casenghi M, Detjen AK, et al. Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update. Clin Infect Dis. 2015;61Suppl 3(Suppl 3):S179–87.
- Wills GH, Graham SM, Seddon JA, Welch SB, McGowan C, Turkova A, et al., editors. A method for baseline adjudication of tuberculosis diagnosis in children in a therapeutic clinical trial: experience from SHINE 51st World Conference on Lung Health; 2020. Virtual.
- U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 20. 2014. Nov, [accessed 16 August 2020]. .
- WHO. Geneva: 2012. (Global Tuberculosis Report).
- Kekitiinwa A, Cook A, Nathoo K, Mugyenyi P, Nahirya-Ntege P, Bakeera-Kitaka S, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013;381(9875):1391–403.
- WHO. Geneva: 2019. (Global tuberculosis report 2019). [Available from: .
- Teo SK, Tan KK, Khoo TK. Four-month chemotherapy in the treatment of smear-negative pulmonary tuberculosis: results at 30 to 60 months. Annals of the Academy of Medicine, Singapore. 2002;31(2):175–81.
- Hong Kong Chest Service/Madras Tuberculosis Rearsrch Centre/British MRC. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. The American review of respiratory disease. 1989;139(4):871–6.
- Hong Kong Chest Service/Madras Tuberculosis Rearsrch Centre/British MRC. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months. The American review of respiratory disease. 1984;130(1):23–8.
- Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24(11):1708–15.
- Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. The New England journal of medicine. 2021;384(18):1705–18.
- Alliance T. Global Alliance for TB drug development (TB Alliance) New milestone for children with tuberculosis reached as one million treatments of child-friendly medicines are ordered. 2019. [Available from: .
- WHO. WHO consolidated guidelines on tuberculosis Module 3: Diagnosis-Rapid diagnostics for tuberculosis detection. 2020. [Available from: .
- Blakemore R, Nabeta P, Davidow AL, Vadwai V, Tahirli R, Munsamy V, et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. American journal of respiratory and critical care medicine. 2011;184(9):1076–84.
Source: PubMed